52 related articles for article (PubMed ID: 12856462)
1. Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.
Horrow C; Gabriele SME; Tu SS; Sarpatwari A; Kesselheim AS
JAMA Intern Med; 2024 Jul; 184(7):810-817. PubMed ID: 38739386
[TBL] [Abstract][Full Text] [Related]
2. Limiting "evergreening" for a better balance of drug innovation incentives.
Stanbrook MB
CMAJ; 2013 Aug; 185(11):939. PubMed ID: 23877665
[No Abstract] [Full Text] [Related]
3. Landscape Analysis of Generic Availability for Oncologic Drugs.
Kumar V; Wang F; Hu M; Kluetz P; Zhao L
Ther Innov Regul Sci; 2023 Nov; 57(6):1279-1286. PubMed ID: 37561261
[TBL] [Abstract][Full Text] [Related]
4. Pre-ANDA strategy and Human Factors activities to de-risk pharmaceutical companies ANDA submission of drug-device combination products: case study of a formative Comparative Use Human Factors study.
Brunet-Manquat L; Combedazou A; Ahuja B; Maden A; Ramus C; Mardovina T; Frolet C
Expert Opin Drug Deliv; 2024 May; 21(5):767-778. PubMed ID: 38753579
[TBL] [Abstract][Full Text] [Related]
5. Common chemistry, manufacturing, and control deficiencies in abbreviated new drug applications assessed by the US Food and drug administration: Hurdle to access cost-effective medicines.
Kulkarni SB; Gaikwad VL
J Pharmacol Toxicol Methods; 2023; 123():107295. PubMed ID: 37468082
[TBL] [Abstract][Full Text] [Related]
6. Generic Drug Shortage in Japan: GMP Noncompliance and Associated Quality Issues.
Izutsu KI; Ando D; Morita T; Abe Y; Yoshida H
J Pharm Sci; 2023 Jul; 112(7):1763-1771. PubMed ID: 36965844
[TBL] [Abstract][Full Text] [Related]
7. J&J patent decision to enable generic tuberculosis treatment.
Burki T
Lancet; 2023 Oct; 402(10410):1313. PubMed ID: 37839412
[No Abstract] [Full Text] [Related]
8. The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020.
Kannappan S; Darrow JJ; Kesselheim AS; Beall RF
Clin Transl Sci; 2021 Sep; 14(5):1917-1923. PubMed ID: 33982425
[TBL] [Abstract][Full Text] [Related]
9. Thyroxine and treatment of hypothyroidism: seven decades of experience.
Mateo RCI; Hennessey JV
Endocrine; 2019 Oct; 66(1):10-17. PubMed ID: 31321670
[TBL] [Abstract][Full Text] [Related]
10. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
[TBL] [Abstract][Full Text] [Related]
11. Hatch-Waxman in the Federal Courts: from 1994--2004.
Ludwig SP; Kosinski KB; Harris J
Drug Dev Ind Pharm; 2005 Jan; 31(2):215-22. PubMed ID: 15773288
[TBL] [Abstract][Full Text] [Related]
12. Generic Drugs and the Struggle to Compete: The Role of Skinny Labels.
Boumil MM; Beninger P
Clin Ther; 2024 May; 46(5):420-423. PubMed ID: 38796336
[TBL] [Abstract][Full Text] [Related]
13. FDA's proposed rules on patent listing requirements for new drug and 30-month stays on ANDA approval (proposed Oct. 24, 2002).
Hui YF
Ann Health Law; 2003; 12(2):325-40, table of contents. PubMed ID: 12856462
[TBL] [Abstract][Full Text] [Related]
14. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
[TBL] [Abstract][Full Text] [Related]
15. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
